Smoking Cessation and Hospitalized Patients: A Missed Opportunity to Avoid Premature Deaths

Roger J. Zoorob, MD, MPH,1 Robert S. Levine, MD,1,2 Charles H. Hennekens, MD, DrPH1,3

1Department of Family and Community Medicine, Baylor College of Medicine, Houston, TX 2Affiliate Professor, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL 3First Sir Richard Doll Professor and Senior Academic Advisor to the Dean, Charles H. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL

INTRODUCTION

Professor Sir Richard Doll, in collaboration with Professor Sir Austin Bradford Hill, were the first to quantitate the relationship of cigarette smoking with lung cancer.1 Later, Doll aptly stated, “Death in old age is inevitable, but death before old age is not.”1 The Richard Doll Building at the University of Oxford in Oxford, England, is inscribed with one of Doll’s many impactful statements about cigarette smoking: “In previous centuries, 70 years used to be regarded as humanity’s allotted span of life, and only about one in five lived to such an age. Nowadays, however, for nonsmokers in Western countries, the situation is reversed: only about one in five will die before 70, and the nonsmoker death rates are still decreasing, offering the promise, at least in developed countries, of a world where death before 70 is uncommon.”1

Despite this evidence-based optimism, cigarette smoking and the emerging clinical and public health challenges of overweight and obesity and physical inactivity are the leading avoidable causes of premature death in most industrialized nations. These risk factors are also emerging in the rest of the world, so that smoking, overweight and obesity, and physical inactivity are the major contributors to the reason that cardiovascular disease (CVD) has increased from number 5 to number 1 as the cause of mortality worldwide.2

In the United States during the past several decades (since 1965), the prevalence of cigarette smoking has decreased markedly.3 Nonetheless, in 2018, approximately 34.2 million Americans aged 18 years and older, or 13.7% of the population, were current cigarette smokers.3 Thus, the impact of cigarette smoking on avoidable and premature mortality remains alarmingly high. In the United States alone, smoking causes more than 480,000 deaths each year.3 These sobering statistics reflect, in major ways, the approximate 2-fold increased risk of CVD among current smokers and the approximate 20-fold increased risk of lung cancer among long-term smokers. Specifically, these relative increases translate to absolute increases of more than 150,000 deaths per year from CVD and 130,000 deaths per year from lung cancer among persons ≥35 years of age.4

Quitting smoking before age 40 years reduces the risk of dying from cigarette-related disease by approximately 90%.5 Specifically, smoking cessation significantly reduces the risks of CVD—beginning within a matter of months—and the risk of CVD among those who quit smoking equals that of lifelong nonsmokers within a few years, even among older adults.6 In contrast, reductions in mortality risk from lung cancer only begin to appear several years after quitting, and even by 10 years, the risk has been reduced to only approximately midway between continuing smokers and lifelong nonsmokers.7

In the United States in 2016, approximately 30 million hospital admissions occurred among persons 18 years of age, with an average length of stay of 4.6 days.8 A 2009 study in San Francisco reported the prevalence of cigarette smoking among hospitalized patients to be 40%9 in contrast to the prevalence in the general population of 13.7%.10 This prevalence implies that up to 12 million inpatients in US hospitals are smokers. In this paper, we discuss effective and safe counseling and drug therapies that have the potential to prevent numerous premature deaths in the United States caused by cigarettes in hospitalized smokers.

SMOKING CESSATION COUNSELING

A systematic review of smoking cessation counseling studies examined 340 peer-reviewed publications of intensive smoking cessation programs for hospitalized patients and found that 326 (95.9%) did not meet quality standards.11 Among the remaining 14 studies, 8 showed no difference between the intervention and comparison groups.12-19 Three studies included self-reported and biochemically tested abstinence and reported positive results based on self-reports but not on biochemical testing.20-22 Two other studies reported positive results based on self-reports but did not include biochemical testing.23,24 However, a trial that randomized hospitalized adult smokers, identified by their desire to quit, to intensive vs standard counseling during hospitalization and after discharge resulted in higher rates of...
smoking cessation at 6 months in the intensive counseling
group.25

For the intensive counseling group, postdischarge inter-
ventions included automated telephone calls and free med-
ication. Prescription drug therapy was individualized for the
intervention group, and patients received 5 automated out-
bound interactive voice response telephone calls at 2, 14,
30, 60, and 90 days after discharge. These telephone calls
provided advice and support messages prompting smok-
ers to stay quit, encouraging proper use and adherence to
cessation medication, offering medication refills, and triag-
ing patients who needed live support from counselors. An
automated telephone script reinforced these messages and
encouraged participants to request a callback from a coun-
selor if they had low confidence in their ability to stay quit,
had resumed smoking but still wanted to quit, needed a
medication refill, or were noncompliant. The drug or drugs
prescribed were documented in the medical record to alert
the attending physician, and a fax was sent to the patient’s
primary care clinician as well. In contrast, standard care
included postdischarge recommendations, advice to call a
free telephone quit line, and a note in the medical record
advising hospital physicians to prescribe smoking cessation
medication at discharge.25

Short- and long-term results were based on biochemically
confirmed abstinence at discharge and at 6-month follow-
up. At 6 months, 26% of patients in the intensive counseling
group had stopped smoking vs 15% of patients in the stan-
dard counseling group.25 This difference was highly signifi-
cant but more important was its clinical and public health sig-
nificance. Specifically, this relative reduction could translate
into an absolute reduction of 1.32 million cigarette smokers
among hospitalized patients in the United States.3,8-10

DRUG THERAPIES

The US Food and Drug Administration (FDA) has approved
7 prescription and over-the-counter drug therapies for smok-
ing cessation.26 Perhaps the most effective is the pre-
scription medication varenicline that achieved permanent
quit rates at 12 weeks of approximately 25% and was
approved by the FDA in 2006. In 2009, however, varenicline
received a black box warning based on reports to the FDA
Adverse Event Reporting System (AERS) of neuropsychiatric
symptoms including aggression, depression, and suicidal
ideation. Data from the AERS are useful for formulating but
not for testing hypotheses, and analysis showed that nearly
half of the subjects had psychiatric histories, 42% were tak-
ing psychotropic drugs, and 42% had depression.27

The adverse public health impact of the black box warn-
ing was substantial, leading to a 76% decline in the num-
ber of prescriptions dispensed, from a peak of approximately
2 million in the last quarter of 2007 to approximately 531,000
in the first quarter of 2014.27 Gaballa et al estimated that
because of the decrease in prescription rates, an estimated
17,000 annual US deaths from CVD attributable to smoking
were avoidable between 2009 and 2016.27

In 2016, the FDA removed the black box warning, based,
in large part, on the results of the Evaluating Adverse Events
in a Global Smoking Cessation Study (EAGLES), a random-
ized trial of adequate size and 12 weeks’ duration.28 With
respect to efficacy, varenicline was statistically significantly
superior to bupropion and the nicotine patch, and bupro-
pion and the patch were superior to placebo. Regarding
side effects, varenicline produced no significant increases
in serious neuropsychiatric symptoms in either the gen-
eral population or patients with mental illness. The finding
among patients with mental illness was especially impor-
tant because the lifespan of patients with schizophrenia
is reduced by approximately 20% compared to the gen-
eral population.29 Although high premature death rates in
patients with schizophrenia had been attributable to their 10-
fold increase risk of suicide, patients with schizophrenia have
a 40% or greater death rate from CVD that is attributable, in
large part, to the approximate 74% rate of cigarette smok-
ing among patients with schizophrenia, combined with over-
weight and obesity and physical inactivity.29

BENEFIT OF MULTIFACTORIAL INTERVENTIONS

Providing multifactorial intensive counseling interventions
during and after hospitalization and initiating and maintain-
ing adherence to drug therapy are independently associated
with permanent cessation rates.30 Among 9,193 smokers
hospitalized for myocardial infarction and identified by the
largest US registry, 97% received smoking cessation coun-
seling during hospitalization, but only 7% filled their smok-
ing cessation prescription within 90 days of discharge, and
by 1 year, the percentage had only increased to 9.4%.31 In
a Veterans Affairs hospital network, only 33.7% of patients
with chronic obstructive pulmonary disease were prescribed
a smoking cessation medication, and among these patients,
53.4% received nicotine patches alone.32 In another study
involving 36,675 patients with coronary heart disease, only
22.7% (8,316) received any smoking cessation pharma-
caceutical during the hospitalization.33

Implementation of effective and safe antismoking campa-
igns has been suboptimal in communities as well as in
hospitals. For example, among an estimated 53,107,842
active smokers with chronic obstructive pulmonary disease,
the average prescription rate for smoking cessation efforts
was 3.64%.34 Among smokers with peripheral artery dis-
ease, approximately 64% received no counseling or phar-
macotherapy for smoking cessation.35

In theory, achieving 90% coverage with smoking ces-
sation programs would save approximately 1,300,000
quality-adjusted life-years.36 This estimate is greater than
the combined effects of screening for breast, colon, and
cervical cancers; chlamydia; cholesterol; problem drinking;
and vision.36 The health care system in the United States
is characterized by numerous high-cost, low-value services
such as baseline laboratory tests for low-risk patients hav-
ing low-risk surgery ($227.8 million per year in unnecessary
costs); stress cardiac or other cardiac imaging in low-risk
asymptomatic patients ($93.2 million); annual electrocardio-
grams or other cardiac screening for low-risk asymptomatic
patients ($41.0 million); and routine head computed tomog-
raphy scans for emergency department visits for patients
with dizziness ($24.8 million).37 In contrast, smoking ces-
sation programs are cost-effective, in part, because the
benefits to the economy far exceed the monetary value of
the delivery of the effective multifactorial interventions.36,38

CONCLUSION

The totality of evidence suggests that initiation of
long-term counseling and adjunctive drug therapy during
hospitalization and maintaining high adherence postdischarge can markedly improve permanent quit rates with minimal to no side effects. Programs should include long-term counseling and at least a 90-day prescription of a smoking cessation medication, preferably varenicline. Such efforts have the potential to reduce the number of avoidable premature deaths from cigarette smoking that remains alarmingly and unnecessarily high in the United States and worldwide.

ACKNOWLEDGMENTS

Professors Zoorob and Levine have no disclosures. Professor Hennekens reports that he serves as an independent scientist in an advisory role to investigators and sponsors as chair of data monitoring committees for Amgen, British Heart Foundation, Cadila, Canadian Institutes of Health Research, DalCor, and Regeneron and to the Collaborative Institutional Training Initiative, legal counsel for Pfizer, the United States Food and Drug Administration, and UpToDate. Professor Hennekens receives royalties for authorship or editorship of 3 textbooks and as co-inventor on patents for inflammatory markers and cardiovascular disease that are held by Brigham and Women’s Hospital. He has an investment management relationship with the West-Bacon Group held by Brigham and Women’s Hospital. He has an investment authority, but he does not own any common or preferred stock in any pharmaceutical or medical device company.

REFERENCES

1. Peto R, Beral V. Richard Shaboe Doll. In: Goldman L, ed. Oxford Dictionary of National Biography 2005-2008. Oxford University Press; 2013:315-318.
2. Hennekens CH, Andreotti F. Leading avoidable cause of premature deaths worldwide: case for obesity. Am J Med. 2013;126(2):97-98. doi:10.1016/j.amjmed.2012.06.018
3. Creamer MR, Wang TW, Babb S, et al. Tobacco product use and cessation indicators among adults – United States, 2018. MMWR Morb Mortal Wkly Rep. 2019;68(45):1013-1019. doi:10.15585/mmwr.mm6845a2
4. National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. The Health Consequences of Smoking—50 Years of Progress: A Report of The Surgeon General. Centers for Disease Control and Prevention (US); 2014. www.ncbi.nlm.nih.gov/books/NBK179276/
5. Health benefits of quitting smoking over time. American Cancer Society. Accessed May 29, 2020. www.cancer.org/healthy/stay-away-from-tobacco/benefits-of-quitting-smoking-over-time.html
6. LaCroix AZ, Lang J, Scherr P, et al. Smoking and mortality among older men and women in three communities. N Engl J Med. 1991;324(23):1619-1625. doi:10.1056/NEJM199106063242303
7. Tobacco: health benefits of smoking cessation. World Health Organization. February 25, 2020. Accessed October 20, 2020. www.who.int/news-room/q-a-detail/health-benefits-of-smoking-cessation
8. Freeman WJ, Weiss AJ, Heslin KC. Statistical brief #246. Overview of U.S. hospital stays in 2016: variation by geographic region. Agency for Healthcare Research and Quality. December 2018. www.hcup-us.ahrq.gov/reports/statb Briefs/sb246-Geographic-Variation-Hospital-Stays.jsp
9. Benowitz NL, Schultz KE, Haller CA, Wu AHB, Dains KM, Jacob P III. Prevalence of smoking assessed biochemically in an urban public hospital: a rationale for routine cotinine screening. Am J Epidemiol. 2009;170(7):885-891. doi:10.1093/aje/kwp215
10. Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion. Current cigarette smoking among adults in the United States. Centers for Disease Control and Prevention. Accessed October 4, 2020. www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm
11. do Amaral LM, de Macêdo ÁCDAD, Lanzieri IO, Andrade RO, Richter KP, Leite ICg. Promoting cessation in hospitalized smoking patients: a systematic review. Rev Assoc Med Bras (1992). 2020;66(6):849-860.
12. Reid RD, Pipe AL, Quinlan B, Oda J. Interactive voice response telephony to promote smoking cessation in patients with heart disease: a pilot study. Patient Educ Couns. 2007;66(3):319-326. doi:10.1016/j.pec.2007.01.005
13. Regan S, Reyen M, Lockhart AC, Richards AE, Rigotti NA. An interactive voice response system to continue a hospital-based smoking cessation intervention after discharge. Nicotine Tob Res. 2011;13(4):255-260. doi:10.1093/ntr/ntq248
14. Cummins SE, Gamst AC, Brandstein K, et al. Helping hospitalized smokers: a factorial RCT of nicotine patches and counseling. Am J Prev Med. 2016;51(4):578-586. 10.1016/j.amepre.2016.06.021
15. Fellows JL, Mularski RA, Leo MC, et al. Referring hospitalized smokers to outpatient quit services: a randomized trial. Am J Prev Med. 2016;51(4):609-619. doi:10.1016/j.amepre.2016.06.014
16. Harrington KF, Kim Y, Chen M, et al. Web-based intervention for transitioning smokers from inpatient to outpatient care: an RCT. Am J Prev Med. 2016;51(4):620-629. doi:10.1016/j.amepre.2016.04.008
17. Richter KP, Faseru B, Shierman T, et al. Warm handoff versus fax referral for linking hospitalized smokers to quitlines. Am J Prev Med. 2016;51(4):587-596. doi:10.1016/j.amepre.2016.04.006
18. Busch AM, Tookey EM, Dunsiger S, et al. Behavioral activation for smoking cessation and mood management following a cardiac event: results of a pilot randomized controlled trial. BMC Public Health. 2017;17(1):323. doi:10.1186/s12889-017-4250-7
19. Cruvinel E, Richter KP, Colugnati F, Ronzani TM. An experimental feasibility study of a hybrid telephone counseling/text messaging intervention for post-discharge cessation support among hospitalized smokers in Brazil. Nicotine Tob Res. 2019;21(12):1700-1705. doi:10.1093/ntr/nty165
20. Hennikus DJ, Lando HA, McCarty MC, et al. The TEAM project: the effectiveness of smoking cessation intervention with hospital patients. Prev Med. 2005;40(3):249-258. doi:10.1016/j.ypmed.2004.05.030
21. Rigotti NA, Tindle HA, Regan S, et al. A post-discharge smoking-cessation intervention for hospital patients: Helping HAND 2 randomized clinical trial Am J Prev Med. 2016;51(4):597-608. doi:10.1016/j.amepre.2016.04.005
22. Thomas D, Abramson MJ, Bonevski B, et al. Integrating smoking cessation into routine care in hospitals—a randomized controlled trial. Addiction. 2016;111(4):714-723. doi:10.1111/add.13239
23. Dornelas EA, Sampson RA, Gray JF, Waters D, Thompson PD. A randomized controlled trial of smoking cessation counseling after myocardial infarction. Prev Med. 2000;30(4):261-268. doi:10.1006/pmed.2000.0644
24. Sherman SE, Link AR, Rogers ES, et al. Smoking-cessation interventions for urban hospital patients: a randomized
25. Rigotti NA, Regan S, Levy DE, et al. Sustained care intervention and post discharge smoking cessation among hospitalized adults: a randomized clinical trial. *Am J Prev Med*. 2016;51(4):566-577. doi: 10.1016/j.amepre.2016.06.023

26. Behavioral health and tobacco cessation. American Academy of Family Physicians. Accessed May 29, 2020. https://www.aafp.org/patient-care/public-health/tobacco-nicotine/office-champions/behavioral-health.html

27. Gaballa D, Drowos J, Hennekens CH. Smoking cessation: the urgent need for increased utilization of varenicline. *Am J Med*. 2017;130(4):389-391. doi:10.1016/j.amjmed.2016.11.015

28. Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomized, placebo-controlled clinical trial. *Lancet*. 2016;387(10037):2507-2520. doi:10.1016/S0140-6736(16)30272-0

29. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risk of cardiovascular disease. *Am Heart J*. 2005;150(6):1115-1121. doi:10.1016/j.ahj.2005.02.007

30. Liebmann EP, Scheuermann TS, Faseru B, Richter KP. Critical steps in the path to using cessation pharmacotherapy following hospital-initiated tobacco treatment. *BMC Health Serv Res*. 2019;19(1):246. doi:10.1186/s12913-019-4059-4

31. Pagidipati NJ, Hellkamp A, Thomas L, Gulati M, Peterson ED, Wang TY. Use of prescription smoking cessation medications after myocardial infarction among older patients in community practice. *JAMA Cardiol*. 2017;2(9):1040-1042. doi:10.1001/jamacardio.2017.2369

32. Melzer AC, Feemster LC, Collins MP, Au DH. Utilization and effectiveness of pharmacotherapy for tobacco use following admission for exacerbation of COPD. *J Hosp Med*. 2016;11(4):257-263. doi:10.1002/jhm.2519

33. Pack QR, Priva A, Lagu TC, Pekow PS, Rigotti NA, Lindenauer PK. Smoking cessation pharmacotherapy among smokers hospitalized for coronary heart disease. *JAMA Intern Med*. 2017;177(10):1525-1527. doi:10.1001/jama.2017.5485

34. Kwak MJ, Kim J, Bhise V, Chung TH, Petitto GS. National trends in smoking cessation medication prescriptions for smokers with chronic obstructive pulmonary disease in the United States, 2007-2012. *J Prev Med Public Health*. 2018;51(5):257-262. doi:10.3961/jpmph.18.1119

35. Berger JS, Ladapo JA. Underuse of prevention and lifestyle counseling in patients with peripheral artery disease. *J Am Coll Cardiol*. 2017;69(18):2293-2300. doi:10.1016/j.jacc.2017.02.064

36. Maciosek MV, Edwards NM, Coffield AB, et al. Priorities among effective clinical preventive services: methods. *Am J Prev Med*. 2006;31(1):90-96. doi:10.1016/j.amepre.2006.03.011

37. Mafi JN, Russell K, Bortz BA, Dachary M, Hazel WA Jr, Fendrick AM. Low-cost, high-volume health services contribute the most to unnecessary health spending. *Health Aff (Millwood)*. 2017;36(10):1701-1704. doi:10.1377/hlthaff.2017.0385

38. Woolf SH. The price paid for not preventing diseases. In: Yong PL, Saunders RS, Olsen L, eds. *The Healthcare Imperative: Lowering Costs and Improving Outcomes: Workshop Series Summary*. National Academies Press; 2010:220-225.